ASPOFAFF :: Journal - Volume 1 :: Issue 2 :: Vol 1 - Iss 2 - Short Communication - Treatment of Bipolar Disorder Patients with Atypical Antipsychotic Aripiprazole


	Home


	Shopping Cart


	Contact Us


	IRBD.ORG


	EUBF.ORG

All Enquiries:: +44 (0)20 8487 1421

Search:

Advanced search

Printable version

Categories

Help

ASPOFAFF :: Journal - Volume 1 :: Issue 2 :: Vol 1 - Iss 2 - Short Communication - Treatment of Bipolar Disorder Patients with Atypical Antipsychotic Aripiprazole

Vol 1 - Iss 2 - Short Communication - Treatment of Bipolar Disorder Patients with Atypical Antipsychotic Aripiprazole #27

Treatment of Bipolar Disorder Patients with Atypical Antipsychotic Aripiprazole

O. Dyutin MD, R. Rosillo MD, I. Skvirski MD, PhD, Mikhail Azrilevich, MD: New Life Community Health Services, Philadelphia, PA, USA
Temple University Health System Philadelphia, PA, USA

This retrospective study presents a treatment analysis with the atypical antipsychotic Aripiprazole performed in a combination of mental and physical health care delivery environments. To establish optimal follow up and coordination of care we engaged a collaborative effort between psychiatrists and family practice physicians in terms of determining the efficacy of treatment and establishing a medication side effect profile in routine daily practice.

A random sample of 125 patients with different emotional problems who visited our community mental health clinic was selected. Demographic and clinical variables of these patients were obtained from the primary care physicians. Outcome measures included general response, metabolic and nutritional changes, side effects and specific results of treating patients with a new antipsychotic drug.

Patients responded to treatment with Aripiprazole by demonstrating lowered psychotic manifestations (87%), decreased suicidal ideations (92%) and improved cognitive functioning (78%). We did not observe significant changes in glycemic control or plasma lipid profiles. A mean weight decrease was noted in patients taking Aripiprazole during the treatment period.

Conclusions: The new antipsychotic Aripiprazole appears to be safe and therapeutic in the treatment of psychotic manifestations.

Details

Price: €0.01

Options

Quantity

Add to cart

Send to friend

Your name: *

Your e-mail: *

Recipient's e-mail: *

Send to friend

Your cart

	Cart is empty

View cart
Checkout

Authentication

Username

Password

Recover password

If Javascript is disabled in your browser click here